Apimostinel
This is an old revision of this page, as edited by 84.106.113.160 (talk) at 13:47, 22 September 2014 (→See also). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
NRX-1074 is a selective partial agonist of the glycine site of the NMDA receptor which is under development by Naurex for the treatment of major depressive disorder (MDD).[1][2][3] Its mechanism of action and effects are similar to those of GLYX-13 – which is under development as an adjunctive therapy for treatment-resistant depression also by Naurex – but NRX-1074 is several thousand times more potent by weight and, unlike GLYX-13, is orally-active.[2] NRX-1074 has shown rapid antidepressant effects in preclinical models of depression.[2] In addition, similarly to GLYX-13, it is well-tolerated, and lacks the schizophrenia-like psychotomimetic effects of the NMDA receptor antagonist ketamine.[2]
As of May 2014, NRX-1074 is in phase IIa clinical trials for MDD.[2]
See also
References
- ^ PR Newswire (2010). "Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch".
- ^ a b c d e PR Newswire (2014). "Naurex Reports Positive Top-Line Phase 2b Results for Novel Antidepressant GLYX-13 and Advances NRX-1074 into Phase 2 Depression Study".
- ^ Dang YH, Ma XC, Zhang JC; et al. (January 2014). "Targeting of NMDA Receptors in the Treatment of Major Depression". Curr. Pharm. Des. PMID 24410564.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link)
External links
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |